Clinical trial
An Open-label Study to Determine the Effect of Oral Doses of KP-001 on Metformin and Midazolam Pharmacokinetics After a Single Oral Administration and to Determine the Effect of Clarithromycin on KP-001 Pharmacokinetics After a Single Oral Administration in Healthy Adult Participants
NCT06227832 is registered in ClinicalTrials.gov with Kaken Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Study to Determine the Effect of Oral Doses of KP-001 on Metformin and Midazolam Pharmacokinetics After a Single Oral Administration and to Determine the Effect of Clarithromycin on KP-001 Pharmacokinetics After a Single Oral Administration in Healthy Adult Participants
- Lead sponsor
- Kaken Pharmaceutical
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 15, 2023
- Completion date
- July 31, 2024
- Enrollment
- 38 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy adults